Juvederm Ultra 2 — Hylacross HA Filler for Fine Lines & Lip Definition

Juvederm Ultra 2 is Allergan’s lightest Hylacross-technology filler — 24 mg/mL cross-linked non-animal hyaluronic acid + 0.3% lidocaine in phosphate-buffered saline. Engineered for mid-dermis placement targeting fine lines, periorbital area, and lip definition. Manufactured in France with CE 0459 marking; also marketed as Juvederm Ultra XC in the US (FDA approved).

Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) is manufactured by Allergan / AbbVie, a France-based medical device and pharmaceutical company established in 1948. The product is part of the Juvederm dermal filler range, which is distributed across multiple international markets. Regulatory status: CE 0459 · FDA approved (as Juvederm Ultra XC) · Class III Medical Device.

Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Allergan / AbbVie’s Patented Hylacross Cross-Linking Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Allergan / AbbVie’s clinical data, Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) delivers 6-12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid dermis placement typically delivers the longer end of the duration range.

Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) is engineered for mid dermis placement. The standard recommended needle is 30G 1/2″, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) regulatory status: CE 0459 · FDA approved (as Juvederm Ultra XC) · Class III Medical Device. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Juvederm Ultra 2 with Lidocaine (2 x 0.55ml) can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Yes — Juvederm Ultra 2 and Juvederm Ultra XC are the same product under different regional names. Allergan markets it as Ultra 2 in the EU/CE-marked markets and as Ultra XC in the FDA-cleared US market. Both share identical 24 mg/mL Hylacross HA formulation with 0.3% lidocaine in 2 x 0.55 mL prefilled syringes manufactured in France. The ‘XC’ suffix simply indicates the lidocaine version for US labelling purposes.